# Trump Advances Marijuana Rescheduling Policy Update > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/trump-marijuana-rescheduling-policy-update/ > **Published:** 2026-04-24T10:09:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:12:56-04:00 > **Clinical Summary:** Explore the latest trump marijuana rescheduling policy update and its impact on cannabis research and clinical practice advancements. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyFederal RegulationMedical Cannabis[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)[Drug Development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) Why This Matters Rescheduling marijuana from Schedule I to a lower schedule would fundamentally alter the regulatory landscape for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and clinical practice. This policy shift could accelerate FDA-approved cannabis therapeutics development and potentially expand legitimate clinical access pathways. Clinical Summary Federal rescheduling would reclassify cannabis from Schedule I (no accepted medical use) to a lower controlled substance category, acknowledging therapeutic potential while maintaining federal oversight. This change would remove significant regulatory barriers that currently impede [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), drug development, and banking services for state-legal cannabis programs. The rescheduling process typically involves DEA review of scientific evidence regarding abuse potential, accepted medical use, and safety profile under medical supervision. Dr. Caplan’s Take “Rescheduling is the single most important policy change that could advance evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) — it would finally allow the rigorous clinical trials we desperately need. Until then, we’re still practicing medicine in a regulatory gray zone that serves neither patients nor science well.” Clinical Perspective 🧠 Clinicians should prepare for potential changes in cannabis access, research opportunities, and regulatory compliance requirements. While rescheduling doesn’t immediately change state medical cannabis programs, it could influence insurance coverage, medical education integration, and standardized dosing research. Monitor developments for timeline and specific schedule designation, as these details will determine practical clinical implications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20moves%20to%20reschedule%20marijuana%20-%20POLITICO%20%40drcaplan&url=https%3A//www.politico.com/news/2026/04/23/trump-moves-to-reschedule-marijuana-00888729)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.politico.com/news/2026/04/23/trump-moves-to-reschedule-marijuana-00888729)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20moves%20to%20reschedule%20marijuana%20-%20POLITICO%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.politico.com/news/2026/04/23/trump-moves-to-reschedule-marijuana-00888729)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.politico.com/news/2026/04/23/trump-moves-to-reschedule-marijuana-00888729](https://www.politico.com/news/2026/04/23/trump-moves-to-reschedule-marijuana-00888729) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related topics does this news cover?](#What_type_of_cannabis-related_topics_does_this_news_cover) - [Why is this considered emerging information worth monitoring?](#Why_is_this_considered_emerging_information_worth_monitoring) - [What does the federal regulation tag indicate?](#What_does_the_federal_regulation_tag_indicate) - [How does this relate to clinical practice?](#How_does_this_relate_to_clinical_practice) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare providers should monitor closely. #### What type of cannabis-related topics does this news cover? The article focuses on policy, federal regulation, medical cannabis, and clinical research aspects. These categories indicate it covers regulatory and clinical developments rather than recreational cannabis topics. #### Why is this considered emerging information worth monitoring? The “Notable Clinical Interest” classification suggests this contains new policy developments or clinical findings that could impact medical cannabis practice. Healthcare providers should stay informed about these developments as they may affect patient care protocols. #### What does the federal regulation tag indicate? The federal regulation classification suggests this news involves changes or developments at the national level regarding cannabis policy. This could include DEA scheduling decisions, FDA guidance, or other federal agency actions affecting medical cannabis. #### How does this relate to clinical practice? As a clinical research and medical cannabis focused article with notable clinical interest, this likely discusses evidence-based findings or policy changes that could influence treatment protocols. Clinicians should review this information to stay current with evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) standards. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump reclassifies state-licensed medical marijuana as less dangerous Schedule III drug](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) Learn how Trump's reclassification of medical marijuana to Schedule III impacts clinical research and patient access. [Read More](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) [Trump Administration Moves to Reclassify Marijuana as Schedule III Drug | National News](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) Detailed coverage of the Trump administration's move to reclassify marijuana and its national implications. [Explore Details](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) [Trump administration reclassifies cannabis in major shift that could expand scientific research – MSN](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) Discover how the Trump administration's cannabis reclassification could expand scientific research opportunities. [Learn More](https://cedclinic.com/federal-cannabis-reclassification-medical-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).